A bipartisan amendment introduced by Representatives Earl Blumenauer (D-OR), Barbara Lee (D-CA), Tom McClintock (R-CA), and Eleanor Holmes Norton (D-DC) to prevent the Department of Justice from using its funds to impede the implementation of cannabis legalization laws was just passed by the House of Representatives.
Senator Tina Smith (D-MN) filed a new bill this week titled “The Substance Regulation and Safety Act.” This bill would deschedule cannabis and require the US Department of Health and Human Services to develop guidelines for cannabis analogous to those for tobacco.
Industry sources say that the House of Representatives is poised to pass the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act this fall. This legislation would decriminalize and deschedule marijuana on a federal level by removing it from the Controlled Substances Act.
The US Food and Drug Administration released preliminary guidance on cannabis-related clinical research, outlining how companies seeking approval of drugs that contain cannabis or its derivatives must follow the traditional drug review and approval process involving clinical trials. The agency is still working on rules for products that contain the cannabis ingredient CBD; the 2018 Farm Bill legalized hemp but not CBD, and the FDA continues to do its due diligence on CBD while the public awaits guidelines on that compound.